Neutropenia  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT01286818: A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
1b
6
Japan
Ramucirumab (IMC-1121B), IMC-1121B, Ramucirumab, LY3009806, Irinotecan, levofolinate, 5-Fluorouracil (5-FU)
Eli Lilly and Company
Colorectal Carcinoma
02/12
03/12
Javelin DLBCL, NCT02951156 / 2016-002904-15: Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated
1b
29
Europe, US, RoW
Avelumab, MSB0010718C, Utomilumab, PF-05082566, Rituximab, Rituxan, Azacitidine, Vidaza, Bendamustine, Treanda, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin
Pfizer, EMD Serono
Diffuse Large B-Cell Lymphoma
12/19
12/19
NCT00555620: Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

Checkmark Sunitinib+capecitabine/cisplatin OR capecitabine/oxaliplatin in adv gastric cancer
Oct 2013 - Oct 2013: Sunitinib+capecitabine/cisplatin OR capecitabine/oxaliplatin in adv gastric cancer
Completed
1
76
RoW
capecitabine, oxaliplatin, sunitinib malate, Sutent, cisplatin
Pfizer
Stomach Neoplasms
08/10
12/11
NCT03503604: A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

Unknown status
1
18
RoW
hPV19 mAb, anti-VEGF mAb, 5-Fluorouracil, Oxaliplatin, Leucovorin, Paclitaxel, Carboplatin, Gemcitabine, Irinotecan
SuZhou Stainwei Biotech Inc.
Solid Tumors
01/19
03/19
FIGHT, NCT03343301: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Checkmark From FIGHT study for advanced solid tumors & FGFR2b-selected gastroesophageal adenocarcinoma
Mar 2020 - Mar 2020: From FIGHT study for advanced solid tumors & FGFR2b-selected gastroesophageal adenocarcinoma
Checkmark Completed P1 portion for gastric/gastroesophageal cancer [FIGHT]
Sep 2018 - Sep 2018: Completed P1 portion for gastric/gastroesophageal cancer [FIGHT]
Completed
1
12
US
Bemarituzumab, FPA144, Modified FOLFOX6, mFOLFOX6
Five Prime Therapeutics, Inc.
Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
01/19
01/19

Download Options